Caribou Biosciences Inc (CRBU) FinancialsCRBUCaribou Biosciences Inc

Evaluating the bottom line, Caribou Biosciences, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -1690.39%, while the net margin is -1619.88%. These profitability ratios, combined with a Return on Equity (ROE) of -78.27%, provide a clear picture of how effectively CRBU converts its operational activities into shareholder value.

In the context of the broader market, CRBU competes directly with industry leaders such as SPRB and HUMA. With a market capitalization of $177.96M, it holds a significant position in the sector. When comparing efficiency, CRBU's gross margin of 100.00% stands against SPRB's N/A and HUMA's -203.20%. Such benchmarking helps identify whether Caribou Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Caribou has shown a significant revenue increase, with Q4 revenue reaching $3.94 million, an 89.4% year-over-year increase, reflecting strong product demand. Despite this, the company continues to report net losses, with a recent net income of -$24.28 million.